	US 12,235,270 B2
	Depleting tumor-specific tregs
Alexander Rudensky, New York, NY (US); and George Plitas, New York, NY (US)
Assigned to MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US)
Filed by Memorial Sloan Kettering Cancer Center, New York, NY (US)
Filed on Aug. 5, 2021, as Appl. No. 17/395,103.
Application 17/395,103 is a division of application No. 16/116,067, filed on Aug. 29, 2018, abandoned.
Application 16/116,067 is a division of application No. 14/698,600, filed on Apr. 28, 2015, granted, now 10,087,259, issued on Oct. 2, 2018.
Claims priority of provisional application 61/985,329, filed on Apr. 28, 2014.
Prior Publication US 2021/0364520 A1, Nov. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/574 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC G01N 33/57426 (2013.01) [C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/76 (2013.01); G01N 2333/7158 (2013.01)]

9 Claims

1. A method of detecting and/or characterizing binding between an anti-CCR8 antibody agent and CCR8, the method comprising steps of:

contacting the anti-CCR8 antibody agent with cells or tissue from a sample; and

detecting binding between the anti-CCR8 antibody agent with CCR8 in or on the cells or tissue;

wherein the contacting is performed in vitro;

wherein the sample is from a tumor in a human subject;

further comprising a step of determining that the detected binding is with CCR8 in or on tumor-infiltrating Treg cells; and

wherein the anti-CCR8 antibody agent comprises a detectable moiety that is a radioactive, fluorescent, chemiluminescent, or phosphorescent moiety.